Articles by Keith A. Betts, PhD

Antihyperglycemic Treatment Patterns for Chronic Kidney Disease and Type 2 Diabetes
ByKeith A. Betts, PhD,Nikolaus G. Oberprieler, PhD, MSc, MBA,Aozhou Wu, PhD,Glen James, PhD,Scott Beeman, PharmD,Alain Gay, MD,Xuanhao He, PhD,David Vizcaya, PhD, MPH This study characterized antihyperglycemic medication use after chronic kidney disease onset among patients with type 2 diabetes to uncover potential unmet needs in clinical practice.

Geographical Variation in Kidney Function Testing and Associations With Health Care Costs Among Patients With Chronic Kidney Disease and Type 2 Diabetes
ByKeith A. Betts, PhD,Jinlin Song, PhD,Jay Elliott, PhD,Neil Warnock, MD, MS, CHCQM,Ryan Farej, BS,Aozhou Wu, PhD,Rakesh Singh, PhD 
Medical Costs for Managing Chronic Kidney Disease and Related Complications in Patients With Chronic Kidney Disease and Type 2 Diabetes
ByKeith A. Betts, PhD,Jinlin Song, PhD,Elizabeth Faust, MBA, MPH,Karen Yang, BA,Yuxian Du, PhD,Sheldon X. Kong, PhD,Rakesh Singh, PhD 
Impact of Atypical Antipsychotic Use Among Adolescents With Attention-Deficit/Hyperactivity Disorder
ByVanja Sikirica, PharmD, MPH,Steven R. Pliszka, MD,Keith A. Betts, PhD,Paul Hodgkins, PhD, MSc,Thomas M. Samuelson, BA,Jipan Xie, MD, PhD,M. Haim Erder, PhD,Ryan S. Dammerman, MD, PhD,Brigitte Robertson, MD,Eric Q. Wu, PhD A retrospective study of the treatment patterns and economic outcomes associated with off-label atypical antipsychotic use in the treatment of adolescents with attention-deficit/hyperactivity disorder.